Efficacy and Safety of Fibroblast Growth Factor‐21 Analogs for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis: A Systematic Review and Meta‐Analysis

Fibroblast growth factor (FGF)‐21 analogs are potential therapeutic candidates for metabolic dysfunction‐associated steatohepatitis (MASH). This systematic review and meta‐analysis aimed to assess the efficacy and safety of the FGF‐21 analogs, efruxifermin, pegbelfermin, and pegozafermin for MASH tr...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical pharmacology and therapeutics 2024-07, Vol.116 (1), p.72-81
Hauptverfasser:	Jeong, Changhyeon, Han, Nayoung, Jeon, Nakyung, Rhee, Su‐jin, Staatz, Christine E., Kim, Min‐Soo, Baek, In‐hwan
Format:	Artikel
Sprache:	eng
Schlagworte:	Fatty Liver - drug therapy Fibroblast Growth Factors - analogs & derivatives Fibroblast Growth Factors - therapeutic use Humans Metabolic Diseases - complications Metabolic Diseases - drug therapy Metabolic Diseases - metabolism Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic Fatty Liver Disease - etiology Non-alcoholic Fatty Liver Disease - metabolism Randomized Controlled Trials as Topic Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!